Pangaea Data raises further funding to accelerate deployment of its breakthrough AI with pharmaceutical companies and hospitals to improve patient outcomes

Novel unsupervised AI is used by Biopharmaceutical and Healthcare organisations to diagnose patients earlier and connect them to the right therapies, clinical trials and drug discovery studies at scale and at 50 times speed and 87.5% accuracy compared to the best existing solutions

London, 28th January 2021 – Pangaea Data has today announced it has raised its second funding round in 12 months, following a year of rapid growth and successful deployment of its product for scientists and clinicians at global pharmaceutical companies and healthcare organisations in the UK and US. The investment was led by deep tech VC firm IQ Capital, who are following on from the previous funding round alongside leading UK venture firm Hambro Perks. New investors in this round include Ascension Ventures and high-profile private investors from the pharmaceutical industry including Sir Peter Job, Dr. Jonathan Milner, Mr. John Taysom and Mr. Arthur Chen.

Pangaea’s Intelligence Extractor (PIE) is based on its proprietary unsupervised AI, which helps its customers in the biopharmaceutical and healthcare industry extract intelligence such as phenotypes (clinical characteristics and symptoms) from doctors’ notes, discharge summaries and other textual data, which comprises 80% of a patient’s electronic health record. This is critical for detecting patients at risk of diseases, finding genes linked to a phenotype in the context of drug or biomarker discovery, recruiting patients for clinical trials and matching the right patients with the right drugs.

PIE reduces the bias observed in supervised approaches and requires significantly less data. Unlike other solutions that operate as black boxes, Pangaea’s work is publicly validated by leading third party clinicians and scientists. Through peer reviewed publications in high impact journals, PIE has demonstrated that it is able to extract intelligence at 50x speed with 87.5% accuracy, which is 30% higher than alternative methodologies such as rule based natural language processing (NLP), keyword extraction and manual means. PIE’s federated framework allows its customers to apply it across multiple data sources while complying with privacy regulations and to find 10x more suitable patients at scale, saving 6-12 months. This increased productivity for end users has led to a significant return on their investment.

This investment will be used to make strategic hires to the technical and commercial teams, increasing the capacity for client delivery and further expanding the company’s presence in the US, from its existing base in San Francisco. It will also facilitate further development of the product for new use cases in the biopharmaceutical industry, such as extracting adverse events from social media, medical blogs and patient reported narratives for pharmacovigilance purposes.

Vibhor Gupta, CEO of Pangaea Data commented: 

“This latest round of investment is a great recognition of our customers’ success through our breakthrough AI and a product focused approach. With our existing investors reaffirming their support of the company and new investors with vast experience in the life sciences industry coming on board, we are on course to achieve our core mission of improving patient outcomes through a highly profitable and sustainable business model. In the past 12 months, the company has grown 15 times through the successful deployment of PIE in the biopharmaceutical industry, partnerships with healthcare data providers and significant contributions to peer review publications, which demonstrates that we are leading in this sector. This funding will accelerate this success by providing the resources to strengthen the team, explore new use cases, and expand into new markets.”

Ed Stacey, Partner at IQ Capital commented:

“The team at Pangaea Data have built on a foundation of academic research in the field of unsupervised AI and have demonstrated the value of its application in understanding and extracting actionable intelligence from patient data. There are countless use cases for this technology, which unlocks the patient data that was previously inaccessible without a vast amount of manual effort or less accurate approaches. This is an incredibly valuable proposition for the pharmaceutical industry and is already having an impact on patient outcomes.”

Tom Bradley, Partner at Hambro Perks said:

“We are delighted to be investing in Pangaea Data.  Our long track record of supporting health-tech businesses means we are well-placed to partner with the talented management team, and to help them realise the next stage of their growth ambitions.  Now, more than ever, the world is recognising the need for accurate, smart and timely medical diagnostic tools, and Pangaea is at the leading edge of technology to deliver this.”

ENDS

About Pangaea

Pangaea Data Limited provides a novel AI based software product to its customers from the biopharmaceutical and healthcare industry for faster identification of patient cohorts based on phenotypes (clinical characteristics and symptoms) from doctors’ notes and such unstructured textual data which comprises 80% of a patient’s electronic health record (EHR). This is critical for detecting patients at risk of diseases, finding genes linked to a phenotype in the context of drug or biomarker discovery, recruiting patients for clinical trials, and matching the right patients with the right drugs. Pangaea has access to more than 500 million patient electronic health records through its partnerships with hospitals and other such providers from the US, UK, Europe, South America and Asia Pacific.

Pangaea is based in San Francisco, London and Hong Kong and was founded by experienced entrepreneurs who have raised more than £130 million through their academic research and is advised by leading experts from industry, Imperial College London and Stanford University.

For more information, please visit www.pangaeadata.ai

About IQ Capital

IQ Capital is a deeptech venture capital firm that invests in thought-leading founders addressing some of the largest problems in the world – across sectors including machine learning & AI, human-machine interfaces, advanced engineering/robotics & materials, health tech & life sciences, fintech and cybersecurity.

IQ Capital’s 45+ portfolio companies are visionaries and dominate their respective markets on a global scale. Our initial investments at Seed and Series A range from £0.25m to £5m, with capacity for follow-on investment up to £30m through our Growth Fund.

Since its launch in 2007, IQ Capital has achieved over 20 exits, to companies including Apple, Facebook, Google, Huawei, Oracle and Becton Dickinson, and several IPOs. IQ Capital has led over 30 investments over the last three years in outstanding companies including Thought Machine, Privitar, CybSafe, Concirrus, Fluidic and Paragraf.

For more information, please visit www.iqcapital.vc

About Hambro Perks

Hambro Perks is a venture firm and asset manager with a diversified portfolio and a growing investment management platform focussed on technology and biotechnology investments.  In addition to their flagship Venture, EIS and co-investment funds, Hambro Perks offers a number of specialist investment funds, including Hambro Perks Environmental Technology, Special Situations and Access, which invests in venture secondaries. Hambro Perks has offices in London, Guernsey and Abu Dhabi.

Hambro Perks builds partnerships with proven domain experts to execute distinctive investment strategies, leveraging the firm’s in-house capabilities and HP’s established platform.

www.hambroperks.com

About Ascension Ventures

Ascension Ventures is an early-stage VC built by exited entrepreneurs to back the next generation of tech and impact founders. Ascension has backed 100+ tech startups to date through their (S)EIS & Institutional Funds.

The Ascension Life Fund is a specialist EIS fund focussing on the convergence in health tech and life sciences, especially between diagnostics, personalised medicine and data science. The Fund invests in post-seed/pre-Series A companies with exceptional founding teams and high growth potential.

https://www.ascensionventures.com/

Media Contacts:

For Pangaea Data: [email protected] 

For Hambro Perks:

Catherine Armstrong

Director of Communications

[email protected]